¡GoConqr estrena diseño! Cuéntanos qué te parece.

Mapa mental

CVD treatments

Karo pham1008 Inglés

Mind map of CVD treatments: hypertension, dyslipidaemia, IHD, HF, thrombosis and AF

Mind map: CVD treatments

Contenido del mapa

CVD treatments

  1. hypertension

    • thiazide diuretics
      • bendroflumethiazide 2.5mg OM
      • inhibit Na reabsorption in the early diluting segment of the distal tubule
        • inhibit the Na/Cl co-transporter
      • side effects: hypokalemia, hyponatremia, hypomagnesaemia, hypercalcemia, hyperuricaemia, hyperglycemia,hyperlipidaemia, impotence(reversible)
    • beta blockers
      • cardioselective: bisoprolol, atenolol; nonselective: propranolol
      • decrease HR and contractile force thus decrease CO
      • vasodilation
      • decrease Na and water retention
      • SE:bradycardia, tiredness, fatigue, lipids, broncospasm, cold hands and feet, lipid soluble-nightmares, masking hypoglycaemia symp in insulin dep DM
    • ACE inhibitors
      • lisinopril 10mg od
      • inhibit the formation of A2 form A1
        • A2 is a potent vasoconstrictor and promotes aldosterone release
      • SE: hyperkalaemia(check U&E), acure renal failure(U&E), first dose hypotension, dry cough, skin rash and angioedema, alter sense of taste
    • angiotensin II receptor antagonists
      • losartan
      • SE: same as ACE inhibitors minus cough and angioedema
    • calcium channel blockers
      • dyhydropyridines: amlodipine&nifedipine
        • vasodilation of coronary and peripheral arteries
      • phenylalkamines: verapamil
        • slow AV nodal conduction
          • reduces HR & CO
        • causes constipation
      • benzothiazipine derivatives: diltiazem
    • alpha 1 antagonists
      • doxazosin up to 16mg od
      • dilate blood vessels and reduce PVR
  2. dyslipidaemia

    • HMG Co A Reductase Inhibitors (statins)
      • simvastatin max 80mg od
      • partially block HMG Co A reductase
      • inhibit biosynthesis in liver
      • metabolised by CYP3A4
      • rhabdomylosis
      • SE: skin reactions, headaches, GI, myalgia
    • fibrates
      • CI in gallbladder disease
      • benzafibrate 400mg/day
      • bind to PPAR alpha on hepatocytes
        • increases VLDL clearance
      • also decrease hepatic TG secretion
      • SE: gi, headache, skin reactions, fatigue
      • increace warfarin conc by binding to albumin
    • bile acid binding agents
      • ionic exchange resins insoluble in water mix with water and take with meal take other meds 1hr before or 4-6hrs after the resin
      • cholestyramine 4-36g/day
      • not absorbed! bind to bile acid in intestine
        • increase bile excretion
      • reduced absorption of fat sol vit & many drugs eg digoxin
      • SE: significant GI
    • cholesterol binding agents
      • ezetimibe 10mg od
      • inhibits absorption of endogenous and biliary cholesterol in the GI
        • this is done using transporter protein NPC1L1
      • SE: headache, abdo pain, diarrhoea
    • nicotinic acid and derivatives
      • poor side effects profile
      • inhibits hepatic TG production and VLDL secretion
  3. IHD

    • stable angina
      • -symptoms usually precipitate by exercise, cold environment and relieved by rest -burning sensation over the sternum, often radiates to the left jaw, shoulder and arm -chest tightness & shortness of breath -30s to 30min
      • modification of disease
        • Antiplatelets
        • ACE inhibitors
        • Statins
      • symptomatic therapy
        • nitrates
          • -dilate veins more then arteries -they reduce cardiac workload (angina) -low oral bioavailability need nitrate free period - 8-12 hours
          • orally: *isosorbide dinitrate 30-120mg daily in 2-3 doses *isosorbide mononitrate 20-120mg daily in 1-2 doses
          • GTN - sublingual glyceryl trinitrate
            • every 5 mins, up to 3 doses in total, if chest pain persists
        • beta blockers
          • reduce myocardial O2 demand and prevent symptoms
        • calcium channel blockers
          • dyhydropyridines - vasodilation & improve coronary blood flow - prevent symptoms verapamil & diltiazem - decrease AV node conduction - reduce cardiac workload
        • potassium channel blockers
          • nicorandil
            • -ATP dependent K channel activation & nitrate like activity -arterial and venous vasodilation may be used as monotherapy or with beta blockers or calcium channel blockers
        • ivabradine
          • HR lowering drug use if beta blockers CI
        • ranolazine
          • adjunctive therapy in patients who are inadequately controlled or intolerant of beta-blockers or calcium channel blockers -reduces calcium overload in ischaemic myocytes through inhibition of the late sodium current
      • surgical procedures
        • Percutaneous transluminal coronary angioplasty (PTCA)
        • coronary artery bypass grafting (CABG)
    • STEMI
      • -burning or chest discomfort even at rest, severe new onset angina or increasing angina that lasts >20 min -pain may radiate to jaw, shoulder and down left arm -may also present with nausea, vomiting, shortness of breath
      • immediate care
        • to remove pain, prevent deterioration, prevent complications and improve cardiac function
        • ECG monitoring
        • oxygen
        • slow IV diamorphine
          • reduce pain and anxiety
        • metoclopramide 10mg IV
          • antiemetic
        • SL or IV nitrate
          • for ischaemic pain
        • clopidogrel 300mg & aspirin 300mg
          • antiplatelet to limit further extension of thrombus
        • restoring patency of the occluded artery
          • percutaneous coronary intervension
          • thrombolytic agent
            • lyse thrombus and restore blood flow + anticoagulant
      • secondary prophylaxis
        • prevent further infraction/death; modification of risk factors
        • antiplatelets
          • eg aspirin, clopidogrel, prasugrel, ticagrelor
          • aspirin inhibits COX enzyme irreversibly by acetylation
            • reduces thromboxane, prostaglandins, and prostaglandins synthesis
          • clopidogrel inhibits platelet aggregation by irreversibly blocking ADP pathway
            • SE: thrombotic thrombocytopenia purpura
          • if patients can't tolerate antiplatelets give warfarin INR 2-3 for up to 4 years
        • Beta-blockers
        • race limiting calcium channel blockers
        • ACE inhibitors
        • Aldosterone antaginists - Eplerenone
        • nitrates
        • lipid lowering treatment
      • initial management - drug therapy
        • glycoprotein IIb/IIIa
        • antiplatelets
        • anticoagulant
        • thrombolytic drugs
          • to break up thrombus and restore blood flow
  4. HF

    • diuretics
      • loop
      • thiazide
      • K sparing
    • ACE inhibitors
    • Angiotensin II antagonists
    • Aldosterone antagonists
    • Beta-blockers
    • Cardiac glycosides
    • other vasodilators
  5. thrombosis

    • Heparin
      • ADR: haemorrage - most common Major bleeding is less common in LMWH thank UFH
      • UFH
        • mixtures of sulfated mucopolysaccharides of variable lengths
        • MOA: prevents the growth and propagation of a formed thrombus
          • -binds to antithrombin: causes conformational change. activation of heparin-antithrombin complex accelerates certain activated clotting factors (9a.10a,11a,12a,thromnin(2a)) -also binds directly to thrombin
      • LMWH
        • more expensive then UFH show similar efficacy
        • MOA: enhance and accelerate the activity of antithrombin on factor Xa. Prevents growth and propagation of formed thrombi.
        • eg enoxaparin, deltaparin, tinzaparin
    • Heparinoids
      • a mixture of low molecular weight sulfated glycosaminoglycans
      • MOA: promotes inhibition of factor Xa by antithrombin but it does not prolong the APTT
      • danaparoid
    • Hirudins
      • eg lepirudin
      • MOA: they bind to the active site on thrombin
    • Fondaparinux
      • MOA: bind to antithrombin and accelerates antithrombin activity factror Xa
    • Vit K antagonists
      • warfarin
      • MOA: bind to the hepatic reductase enzyme that converts vit K to the active form. Inhibits hepatic synthesis of vit K dependent clotting factors
    • Thromobolitycs
      • only indicated in life-thretening acute massive pulmonary embolus
      • MOA: activate plasminogen, thus promote the breakdown of fibrin to fibrinogen
  6. AF

    • Proxymal AF
      • Recurrent, self terminating episodes of AF. Episode <7 days (most resolve within 24h)
      • rhythm control
        • rate control (if rhythm fails)
    • Persistent AF
      • Sustained AF that terminates with cardioversion
      • rate or rhythm control
        • try other if previous fails
    • Permanent AF
      • AF that is long standing, cardioversion failed of not attempted
      • rate control
        • rhythm control (if rate fails)

Información

Descripción
pham1008 Mapa Mental sobre CVD treatments, creado por Karo el 29/04/2013.
Creado por
Karo
Visitas
91
Etiquetas
pham1008
Valoración

Escríbenos

¿Sobre qué es tu mensaje?

¿Qué te parece el nuevo diseño?

¿Te gusta?